Following the idea of incorporating drugs onto the stent surface, several substances have already been used in DESs.
D5. Report on Drugs assessed for DESs to reduce the urinary stents's morbidity, including scientific papers and TS, meetings, WkS and STSM related to the WG5 of the Action (M44).
Leader: Gianluca Ciardelli
Vice-Leader: Martin Järvekülg